Taken together, these data highlight that the molecular machinery in the RIP3-MLKL signaling network differentially contribute to murine models of AH and NAFL/NASH and that RIP1 and RIP3 might be useful biomarkers to distinguish AH from NASH. The gene discussed is MLKL; the disease is metabolic dysfunction-associated steatohepatitis.